首页 > 最新文献

Journal of vascular surgery. Venous and lymphatic disorders最新文献

英文 中文
Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis 比较维生素 K 拮抗剂与非维生素 K 拮抗剂在肠系膜静脉血栓抗凝治疗中的临床疗效。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-05-15 DOI: 10.1016/j.jvsv.2024.101903

Objective

Non-vitamin K antagonist oral anticoagulants have shown similar efficacy and lower bleeding rates than vitamin K antagonists for venous thromboembolism. However, this has not been proven in mesenteric vein thrombosis. This study aimed to compare the clinical outcomes of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.

Methods

Between January 2014 and July 2022, mesenteric vein thrombosis was diagnosed on computed tomography in 225 patients in a tertiary hospital. Among them, a total of 44 patients who underwent long-term anticoagulation therapy over 3 months were enrolled in this study. Patients were divided into two groups based on the anticoagulant used: vitamin K antagonists (Group 1, n = 21) and non-vitamin K antagonist oral anticoagulants (Group 2, n = 23). The efficacy outcomes were symptom recurrence and thrombus resolution on follow-up computed tomography, and the safety outcome was bleeding complications.

Results

The median age of the patients was 56 years (range, 46-68 years), and 52% were men. The most common risk factors were unprovoked intra-abdominal infections (30%). The median duration of anticoagulation therapy was 13 months (20 months in Group 1 vs 6 months in Group 2; P = .076). Of the 44 patients, 17 (39%) received the standard treatment. The median follow-up period was longer in Group 1 than in Group 2 (57 vs 28 months; P = .048). No recurrence of mesenteric vein thrombosis-related symptoms were observed in either group. The median duration of follow-up computed tomography was 31 months (42 months in Group 1 vs 18 months in Group 2; P = .064). Computed tomography revealed complete thrombus resolution, partial resolution, and no changes in 71%, 19%, and 10%, respectively (P = .075). Regarding bleeding complications, varix bleeding and melena developed in two patients in Group 2, and anticoagulation treatment thereafter ceased.

Conclusions

Despite the short follow-up duration in the non-vitamin K antagonist oral anticoagulants group, there was no clinically significant difference in the thrombus resolution rate or bleeding complications when compared with the vitamin K antagonists group. Although research on the long-term effects of non-vitamin K antagonist oral anticoagulants in patients is limited, non-vitamin K antagonist oral anticoagulants can be considered an alternative to conventional treatments.

目的:与维生素 K 拮抗剂相比,非维生素 K 拮抗剂口服抗凝剂对静脉血栓栓塞症的疗效相似,出血率更低。然而,这在肠系膜静脉血栓中尚未得到证实。本研究旨在比较维生素K拮抗剂和非维生素K拮抗剂口服抗凝药的临床疗效:方法:2014 年 1 月至 2022 年 7 月期间,某三甲医院有 225 例患者经计算机断层扫描确诊为肠系膜静脉血栓。其中,本研究共纳入 44 名接受 3 个月以上长期抗凝治疗的患者。根据使用的抗凝剂将患者分为两组:维生素 K 拮抗剂(第 1 组,n = 21)和非维生素 K 拮抗剂口服抗凝剂(第 2 组,n = 23)。疗效指标为症状复发和随访计算机断层扫描血栓消退,安全性指标为出血并发症:患者年龄中位数为 56 岁(46-68 岁),52% 为男性。最常见的风险因素是无诱因的腹腔内感染(30%)。抗凝治疗的中位持续时间为 13 个月(第 1 组为 20 个月,第 2 组为 6 个月;P = 0.076)。44 名患者中,17 人(39%)接受了标准治疗。第一组的中位随访时间长于第二组(57 个月对 28 个月,P = 0.048)。两组患者均未发现肠系膜静脉血栓相关症状复发。计算机断层扫描的中位随访时间为 31 个月(第一组为 42 个月,第二组为 18 个月;P = 0.064)。计算机断层扫描显示血栓完全消退、部分消退和无变化的比例分别为 71%、19% 和 10%(p = 0.075)。在出血并发症方面,第 2 组的 2 名患者出现了静脉曲张出血和血色素沉着,随后停止了抗凝治疗:结论:尽管非维生素 K 拮抗剂口服抗凝剂组的随访时间较短,但与维生素 K 拮抗剂组相比,血栓溶解率和出血并发症没有明显的临床差异。虽然有关非维生素 K 拮抗剂口服抗凝剂对患者长期影响的研究有限,但非维生素 K 拮抗剂口服抗凝剂可被视为常规治疗的替代疗法。
{"title":"Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis","authors":"","doi":"10.1016/j.jvsv.2024.101903","DOIUrl":"10.1016/j.jvsv.2024.101903","url":null,"abstract":"<div><h3>Objective</h3><p>Non-vitamin K antagonist oral anticoagulants have shown similar efficacy and lower bleeding rates than vitamin K antagonists for venous thromboembolism. However, this has not been proven in mesenteric vein thrombosis. This study aimed to compare the clinical outcomes of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.</p></div><div><h3>Methods</h3><p>Between January 2014 and July 2022, mesenteric vein thrombosis was diagnosed on computed tomography in 225 patients in a tertiary hospital. Among them, a total of 44 patients who underwent long-term anticoagulation therapy over 3 months were enrolled in this study. Patients were divided into two groups based on the anticoagulant used: vitamin K antagonists (Group 1, n = 21) and non-vitamin K antagonist oral anticoagulants (Group 2, n = 23). The efficacy outcomes were symptom recurrence and thrombus resolution on follow-up computed tomography, and the safety outcome was bleeding complications.</p></div><div><h3>Results</h3><p>The median age of the patients was 56 years (range, 46-68 years), and 52% were men. The most common risk factors were unprovoked intra-abdominal infections (30%). The median duration of anticoagulation therapy was 13 months (20 months in Group 1 vs 6 months in Group 2; <em>P</em> = .076). Of the 44 patients, 17 (39%) received the standard treatment. The median follow-up period was longer in Group 1 than in Group 2 (57 vs 28 months; <em>P</em> = .048). No recurrence of mesenteric vein thrombosis-related symptoms were observed in either group. The median duration of follow-up computed tomography was 31 months (42 months in Group 1 vs 18 months in Group 2; <em>P</em> = .064). Computed tomography revealed complete thrombus resolution, partial resolution, and no changes in 71%, 19%, and 10%, respectively (<em>P</em> = .075). Regarding bleeding complications, varix bleeding and melena developed in two patients in Group 2, and anticoagulation treatment thereafter ceased.</p></div><div><h3>Conclusions</h3><p>Despite the short follow-up duration in the non-vitamin K antagonist oral anticoagulants group, there was no clinically significant difference in the thrombus resolution rate or bleeding complications when compared with the vitamin K antagonists group. Although research on the long-term effects of non-vitamin K antagonist oral anticoagulants in patients is limited, non-vitamin K antagonist oral anticoagulants can be considered an alternative to conventional treatments.</p></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 5","pages":"Article 101903"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X2400221X/pdfft?md5=bffd86614b972c2b81714e5a70c85cca&pid=1-s2.0-S2213333X2400221X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-CEUS fusion-guided lymphatic mapping as a preoperative strategy for lymphedema patients undergoing lymphaticovenous anastomosis surgery MRI-CEUS 融合引导下的淋巴管图绘制作为淋巴管静脉吻合手术淋巴水肿患者的术前策略
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-05-15 DOI: 10.1016/j.jvsv.2024.101907

Objective

Contrast-enhanced ultrasound (CEUS) is useful in mapping lymphatic vessels in upper limb lymphedema; this study was aimed to evaluate its efficiency in lower limb lymphedema and investigate whether magnetic resonance lymphangiography (MRL) enhance the efficiency of CEUS.

Methods

This retrospective study enrolled 48 patients with lymphedema undergoing lymphaticovenous anastomosis (LVA) surgery who received MRL and/or CEUS in addition to conventional indocyanine green (ICG) lymphangiography. The number of anastomotic sites and the duration per site (DPS) for LVA surgery were described and compared.

Results

Among the 48 patients subjected to analysis, it was observed that 12 (25%), 20 (41.67%), and 16 (33.33%) of them received ICG, ICG+CEUS, and ICG+CEUS+MRL, respectively. The ICG+CEUS group demonstrated a significant increase in the number of LVAs (median, 5; range, 4-7), compared with the ICG group (median, 2; range, 1-4) (P < .001). Moreover, the ICG+CEUS+MRL group exhibited a higher number of LVAs (median, 8; range, 7-8.25) compared with both the ICG+CEUS and ICG groups (P < .001). For lower limb lymphedema, the ICG+CEUS+MRL group displayed an elevated number of LVAs (median, 8; interquartile range, 7-9) (P = .003), in contrast to the ICG group (median, 3; interquartile range, 1.75-4.25). Furthermore, the DPS in the ICG+CEUS+MRL group (median, 50.56; interquartile range, 48.13-59.29) (P = .005) exhibited a remarkable decrease when compared with the ICG group (median, 131.25; interquartile range, 86.75-198.13]).

Conclusions

MRL-CEUS fusion demonstrates superior performance in the identification of lymphatic vessels for lymphedema.

研究目的对比增强超声(CEUS)可用于绘制上肢淋巴水肿的淋巴管图,本研究旨在评估其在下肢淋巴水肿中的效率,并探讨磁共振淋巴管成像(MRL)是否可提高CEUS的效率:这项回顾性研究纳入了 48 名接受淋巴-静脉吻合术(LVA)手术的淋巴水肿患者,他们除了接受传统的吲哚菁绿(ICG)淋巴管造影术外,还接受了 MRL 和/或 CEUS。对 LVA 手术的吻合部位数量和每个部位的持续时间(DPS)进行了描述和比较:在接受分析的 48 例患者中,有 12 例(25%)、20 例(41.67%)和 16 例(33.33%)分别接受了 ICG、ICG+CEUS 和 ICG+CEUS+MRL。与 ICG 组(中位数,2 [范围,1 - 4])相比,ICG+CEUS 组的 LVA 数量显著增加(中位数,5 [范围,4 - 7])(p < .001)。此外,与 ICG+CEUS 组和 ICG 组相比,ICG+CEUS+MRL 组显示出更多的 LVA(中位数,8 [范围,7 - 8.25])(p < .001)。在下肢淋巴水肿方面,ICG+CEUS+MRL 组的 LVA 数量较多(中位数,8 [四分位间范围,7 - 9])(p = .003),而 ICG 组的 LVA 数量较少(中位数,3 [四分位间范围,1.75 - 4.25])。此外,ICG+CEUS+MRL 组的 DPS(中位数,50.56 [四分位间范围,48.13 - 59.29])(p = .005)与 ICG 组(中位数,131.25 [四分位间范围,86.75 - 198.13])相比显著下降:结论:MRL-CEUS 融合在淋巴水肿的淋巴管识别方面表现优异。
{"title":"MRI-CEUS fusion-guided lymphatic mapping as a preoperative strategy for lymphedema patients undergoing lymphaticovenous anastomosis surgery","authors":"","doi":"10.1016/j.jvsv.2024.101907","DOIUrl":"10.1016/j.jvsv.2024.101907","url":null,"abstract":"<div><h3>Objective</h3><p>Contrast-enhanced ultrasound (CEUS) is useful in mapping lymphatic vessels in upper limb lymphedema; this study was aimed to evaluate its efficiency in lower limb lymphedema and investigate whether magnetic resonance lymphangiography (MRL) enhance the efficiency of CEUS.</p></div><div><h3>Methods</h3><p>This retrospective study enrolled 48 patients with lymphedema undergoing lymphaticovenous anastomosis (LVA) surgery who received MRL and/or CEUS in addition to conventional indocyanine green (ICG) lymphangiography. The number of anastomotic sites and the duration per site (DPS) for LVA surgery were described and compared.</p></div><div><h3>Results</h3><p>Among the 48 patients subjected to analysis, it was observed that 12 (25%), 20 (41.67%), and 16 (33.33%) of them received ICG, ICG+CEUS, and ICG+CEUS+MRL, respectively. The ICG+CEUS group demonstrated a significant increase in the number of LVAs (median, 5; range, 4-7), compared with the ICG group (median, 2; range, 1-4) (<em>P</em> &lt; .001). Moreover, the ICG+CEUS+MRL group exhibited a higher number of LVAs (median, 8; range, 7-8.25) compared with both the ICG+CEUS and ICG groups (<em>P</em> &lt; .001). For lower limb lymphedema, the ICG+CEUS+MRL group displayed an elevated number of LVAs (median, 8; interquartile range, 7-9) (<em>P</em> = .003), in contrast to the ICG group (median, 3; interquartile range, 1.75-4.25). Furthermore, the DPS in the ICG+CEUS+MRL group (median, 50.56; interquartile range, 48.13-59.29) (<em>P</em> = .005) exhibited a remarkable decrease when compared with the ICG group (median, 131.25; interquartile range, 86.75-198.13]).</p></div><div><h3>Conclusions</h3><p>MRL-CEUS fusion demonstrates superior performance in the identification of lymphatic vessels for lymphedema.</p></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 5","pages":"Article 101907"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X24002257/pdfft?md5=980ba3393c59d6efba3d47afb5746a64&pid=1-s2.0-S2213333X24002257-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of nonthermal ablation, thermal ablation, and surgical stripping for varicose veins 非热消融、热消融和手术剥脱治疗静脉曲张的临床效果。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-05-15 DOI: 10.1016/j.jvsv.2024.101902

Objective

The purpose of this study was to compare the clinical outcomes of radiofrequency ablation (RFA), cyanoacrylate closure (CAC), mechanochemical ablation (MOCA), and surgical stripping (SS) for incompetent saphenous veins and to determine a suitable treatment modality for a specific clinical situation.

Methods

We retrospectively reviewed the data of patients with varicose veins who underwent RFA, CAC, MOCA, or SS from January 2012 to June 2023. The clinical outcomes, including postoperative complications and the Aberdeen Varicose Vein Questionnaire score, were assessed.

Results

During the study period, 2866 patients with varicose veins were treated. Among them, 1670 patients (57.9%) were women. The mean age was 55.3 ± 12.9 years. RFA, CAC, MOCA, and SS were performed in 1984 (68.7%), 732 (25.4%), 78 (2.7%), and 88 (3.0%) patients, respectively. The complete target vein closure rate after RFA, CAC, and MOCA was 94.5%, 98%, and 98%, respectively. The absence of a target vein after SS was 98%. Deep vein thrombosis developed in four patients: one in the RFA group and three in CAC group. Surgical or endovenous procedure-induced thrombosis occurred in 2.3%, 4.8%, 6.4%, and 2.3% of the patients after RFA, CAC, MOCA, and SS, respectively. Phlebitis along the target vein occurred in 0.2% and 3.8% of patients after RFA and MOCA, respectively. A hypersensitivity reaction occurred in 3.7% of patients after CAC. Readmission was required for two patients who had undergone SS. Transient nerve symptoms developed in five (0.3%), zero, one (1.3%), and two (2.3%) patients after RFA, CAC, MOCA, and SS, respectively. After treatment, the Aberdeen Varicose Vein Questionnaire score improved significantly in all groups.

Conclusions

The clinical outcomes with improvement in quality of life were comparable among the different treatment modalities. The proximity of the nerve or skin to the target vein is the most important factor in selecting a suitable treatment modality.
研究目的本研究旨在比较射频消融术(RFA)、氰基丙烯酸酯闭合术(CAC)、机械化学消融术(MOCA)和手术剥脱术(SS)治疗无功能隐静脉的临床效果,以确定在特定临床情况下适合的治疗方式:我们回顾性研究了 2012 年 1 月至 2023 年 6 月期间接受 RFA、CAC、MOCA 或 SS 治疗的静脉曲张患者的数据。评估了临床结果,包括术后并发症和阿伯丁静脉曲张问卷(AVVQ)评分:研究期间,共有 2866 名静脉曲张患者接受了治疗。其中,1670 名患者(57.9%)为女性。平均年龄为(55.3±12.9)岁。分别有 1,984 例(68.7%)、732 例(25.4%)、78 例(2.7%)和 88 例(3.0%)患者接受了 RFA、CAC、MOCA 和 SS 治疗。RFA、CAC和MOCA术后靶静脉完全闭合率分别为94.5%、98%和98%。SS术后没有靶静脉的比例为98%。4 名患者发生了深静脉血栓,其中 RFA 组 1 人,CAC 组 3 人。RFA、CAC、MOCA和SS术后分别有2.3%、4.8%、6.4%和2.3%的患者发生了手术或静脉内手术诱发的血栓形成。RFA和MOCA术后分别有0.2%和3.8%的患者发生了靶静脉静脉炎。3.7% 的患者在接受 CAC 后出现过敏反应。两名接受过 SS 手术的患者需要再次入院。接受 RFA、CAC、MOCA 和 SS 治疗后,分别有 5 例(0.3%)、0 例、1 例(1.3%)和 2 例(2.3%)患者出现一过性神经症状。治疗后,各组患者的 AVVQ 评分均有明显改善:结论:不同治疗方法的临床效果和生活质量改善程度相当。神经或皮肤与靶静脉的距离是选择合适治疗方式的最重要因素。
{"title":"Clinical outcomes of nonthermal ablation, thermal ablation, and surgical stripping for varicose veins","authors":"","doi":"10.1016/j.jvsv.2024.101902","DOIUrl":"10.1016/j.jvsv.2024.101902","url":null,"abstract":"<div><h3>Objective</h3><div>The purpose of this study was to compare the clinical outcomes of radiofrequency ablation (RFA), cyanoacrylate closure (CAC), mechanochemical ablation (MOCA), and surgical stripping (SS) for incompetent saphenous veins and to determine a suitable treatment modality for a specific clinical situation.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the data of patients with varicose veins who underwent RFA, CAC, MOCA, or SS from January 2012 to June 2023. The clinical outcomes, including postoperative complications and the Aberdeen Varicose Vein Questionnaire score, were assessed.</div></div><div><h3>Results</h3><div>During the study period, 2866 patients with varicose veins were treated. Among them, 1670 patients (57.9%) were women. The mean age was 55.3 ± 12.9 years. RFA, CAC, MOCA, and SS were performed in 1984 (68.7%), 732 (25.4%), 78 (2.7%), and 88 (3.0%) patients, respectively. The complete target vein closure rate after RFA, CAC, and MOCA was 94.5%, 98%, and 98%, respectively. The absence of a target vein after SS was 98%. Deep vein thrombosis developed in four patients: one in the RFA group and three in CAC group. Surgical or endovenous procedure-induced thrombosis occurred in 2.3%, 4.8%, 6.4%, and 2.3% of the patients after RFA, CAC, MOCA, and SS, respectively. Phlebitis along the target vein occurred in 0.2% and 3.8% of patients after RFA and MOCA, respectively. A hypersensitivity reaction occurred in 3.7% of patients after CAC. Readmission was required for two patients who had undergone SS. Transient nerve symptoms developed in five (0.3%), zero, one (1.3%), and two (2.3%) patients after RFA, CAC, MOCA, and SS, respectively. After treatment, the Aberdeen Varicose Vein Questionnaire score improved significantly in all groups.</div></div><div><h3>Conclusions</h3><div>The clinical outcomes with improvement in quality of life were comparable among the different treatment modalities. The proximity of the nerve or skin to the target vein is the most important factor in selecting a suitable treatment modality.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 6","pages":"Article 101902"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial, biological sex, and geographic disparities of venous thromboembolism in the United States, 2016 to 2019 2016-2019 年美国静脉血栓栓塞症的种族、生理性别和地域差异。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-05-15 DOI: 10.1016/j.jvsv.2024.101908

Background

Venous thromboembolism (VTE) stands as the leading cause of preventable death within hospitals in the United States. Although there have been some studies investigating the incidence rates of VTE, there has yet to be a large-scale study elucidating disparities in sex, race, income, region, and seasons in patients with VTE. The goal of this study was to report the disparities in race, sex, income, region, and seasons in patients with VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT), in hospitalized patients from 2016 to 2019.

Methods

We used the United States National Inpatients Sample database to identify inpatients diagnosed with PE, DVT, and PE and DVT from 2016 to 2019. The inpatient incidence per thousand was calculated for sex and race using the weighted sample model. The regional and monthly incidence of DVT and PE per thousand inpatients and risk of incidence were calculated. Patients' characteristics including hospital type, bed size, median length of stay, median total charges, and mortality were also collected.

Results

We examined 455,111 cases of VTE, 177,410 cases of DVT, 189,271 cases of PE, and 88,430 cases of both DVT and PE combined. Over the study period, we observed a statistically significant trend among PE hospitalization incidences. There was a strong and positive correlation between DVT and PE inpatients. Black inpatients had the highest cumulative incidence of hospitalizations in all cohorts with 10.36 per 1000 in PE and 9.1 per 1000 in DVT. Asian and Pacific Islander inpatients had the lowest cumulative incidence with 4.42 per 1000 in PE and 4.28 per 1000 in DVT. Females showed the lowest cumulative incidence with 7.47 per 1000 in PE and 6.53 per 1000 in DVT. The Mountain region was the highest among PE hospitalizations with 9.62 per 1000. For DVT, the Middle Atlantic region was the highest at 8.65 per 1000. The in-hospital mortality rate was the highest among the PE hospitalizations at 7.3%. Also, the trend analysis showed significant increases among all groups.

Conclusions

Over the study period (2016-2019), we report the racial, biological sex, and geographical disparities from the National Inpatient Sample database, highlighting that Black inpatients had the highest incidence of PE and DVT, whereas Asian/Pacific Islander inpatients had the lowest incidences of PE and DVT. Moreover, women had a lower incidence compared with men. The observed regional variations indicated that the incidence of PE was highest in the Mountain region, whereas the incidence of DVT was lowest in the Middle Atlantic region. There was an increase in the mortality of inpatients diagnosed with VTE reflecting the growing burden of this condition in the US health care system.

背景:静脉血栓栓塞症(VTE)是美国医院内可预防死亡的主要原因。虽然有一些研究调查了 VTE 的发病率,但还没有一项大规模的研究阐明 VTE 患者在性别、种族、收入、地区和季节方面的差异。本研究旨在报告 2016-2019 年住院患者中 VTE、肺栓塞(PE)和深静脉血栓(DVT)患者在种族、性别、收入、地区和季节方面的差异:我们利用美国全国住院患者抽样数据库,确定了2016年至2019年确诊为PE、DVT和PE&DVT的住院患者。使用加权样本模型计算了每千人住院病人的性别和种族发病率。计算了每千名住院患者中 DVT 和 PE 的地区和月发病率以及发病风险。此外,还收集了患者的特征,包括医院类型、病床大小、住院时间中位数、总费用中位数和死亡率:我们对 455,111 例 VTE、177,410 例深静脉血栓、189,271 例 PE 以及 88,430 例深静脉血栓和 PE 合并病例进行了研究。在研究期间,我们观察到 PE 住院发病率有明显的统计学趋势。深静脉血栓形成和 PE 住院患者之间存在很强的正相关性。在所有组群中,黑人住院患者的累计住院率最高,PE为10.36/1000,DVT为9.1/1000。亚裔和太平洋岛民住院患者的累计发病率最低,PE 为 4.42/1000,DVT 为 4.28/1000。女性的累计发病率最低,PE 为 7.47/1000 例,DVT 为 6.53/1000 例。山区的 PE 住院率最高,为 9.62/1000。就深静脉血栓而言,中大西洋地区的发病率最高,为 8.65/1000。在 PE 住院病例中,院内死亡率最高,为 7.3%。此外,趋势分析表明,所有组别中的死亡率均有显著上升:在研究期间(2016-2019 年),我们报告了全国住院病人抽样数据库中的种族、生物性别和地域差异,强调黑人住院病人的 PE 和深静脉血栓发生率最高,而亚裔/太平洋岛民住院病人的 PE 和深静脉血栓发生率最低。此外,女性发病率低于男性。观察到的地区差异表明,山区 PE 的发病率最高,而中大西洋地区 DVT 的发病率最低。确诊为 VTE 的住院病人死亡率有所上升,这反映出这种疾病给美国医疗系统带来的负担越来越重。
{"title":"Racial, biological sex, and geographic disparities of venous thromboembolism in the United States, 2016 to 2019","authors":"","doi":"10.1016/j.jvsv.2024.101908","DOIUrl":"10.1016/j.jvsv.2024.101908","url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) stands as the leading cause of preventable death within hospitals in the United States. Although there have been some studies investigating the incidence rates of VTE, there has yet to be a large-scale study elucidating disparities in sex, race, income, region, and seasons in patients with VTE. The goal of this study was to report the disparities in race, sex, income, region, and seasons in patients with VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT), in hospitalized patients from 2016 to 2019.</p></div><div><h3>Methods</h3><p>We used the United States National Inpatients Sample database to identify inpatients diagnosed with PE, DVT, and PE and DVT from 2016 to 2019. The inpatient incidence per thousand was calculated for sex and race using the weighted sample model. The regional and monthly incidence of DVT and PE per thousand inpatients and risk of incidence were calculated. Patients' characteristics including hospital type, bed size, median length of stay, median total charges, and mortality were also collected.</p></div><div><h3>Results</h3><p>We examined 455,111 cases of VTE, 177,410 cases of DVT, 189,271 cases of PE, and 88,430 cases of both DVT and PE combined. Over the study period, we observed a statistically significant trend among PE hospitalization incidences. There was a strong and positive correlation between DVT and PE inpatients. Black inpatients had the highest cumulative incidence of hospitalizations in all cohorts with 10.36 per 1000 in PE and 9.1 per 1000 in DVT. Asian and Pacific Islander inpatients had the lowest cumulative incidence with 4.42 per 1000 in PE and 4.28 per 1000 in DVT. Females showed the lowest cumulative incidence with 7.47 per 1000 in PE and 6.53 per 1000 in DVT. The Mountain region was the highest among PE hospitalizations with 9.62 per 1000. For DVT, the Middle Atlantic region was the highest at 8.65 per 1000. The in-hospital mortality rate was the highest among the PE hospitalizations at 7.3%. Also, the trend analysis showed significant increases among all groups.</p></div><div><h3>Conclusions</h3><p>Over the study period (2016-2019), we report the racial, biological sex, and geographical disparities from the National Inpatient Sample database, highlighting that Black inpatients had the highest incidence of PE and DVT, whereas Asian/Pacific Islander inpatients had the lowest incidences of PE and DVT. Moreover, women had a lower incidence compared with men. The observed regional variations indicated that the incidence of PE was highest in the Mountain region, whereas the incidence of DVT was lowest in the Middle Atlantic region. There was an increase in the mortality of inpatients diagnosed with VTE reflecting the growing burden of this condition in the US health care system.</p></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 5","pages":"Article 101908"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X24002269/pdfft?md5=3ef78a9d1e078d53699726cbd1815b5f&pid=1-s2.0-S2213333X24002269-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indications, technical aspects, and outcomes of stent placement in chronic iliofemoral venous obstruction 慢性髂股静脉阻塞的支架植入适应症、技术方面和效果。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-05-15 DOI: 10.1016/j.jvsv.2024.101904

Background

Iliofemoral venous stent placement (IVS) has evolved to a well-established endovascular treatment modality for chronic iliofemoral venous obstruction (CIVO). Dedicated venous stents gained approval from the US Food and Drug Administration in 2019 and solidified IVS as a defined intervention with clear indications, contraindications, risks, benefits, and procedural management principles. This review focuses on the indications, technical aspects and outcomes of stenting for CIVO. Other aspects pertaining to IVS are covered in other articles that are a part of this series.

Methods

This study conducted a literature search limited to English articles. Three search strategies were used, and references were managed in Covidence software. Four investigators screened and evaluated articles independently, excluding meta-analyses, clinical trial protocols, and nonrelevant studies. Eligible studies, focused on clinical outcomes and stent patencies, underwent thorough review.

Results

The literature search yielded 1704 studies, with 147 meeting eligibility criteria after screening and evaluation. Exclusions were based on duplicates, irrelevant content, and noniliac vein stent placement.

Conclusions

Successful IVS for CIVO relies on meticulous patient selection, consistent use of intravascular ultrasound examination during procedures and attention to the technical details of IVS.

背景:髂股静脉支架置入术(IVS)已发展成为治疗慢性髂股静脉阻塞(CIVO)的一种行之有效的血管内治疗方式。专用静脉支架于 2019 年获得 FDA 批准,巩固了 IVS 的地位,使其成为一种具有明确适应症、禁忌症、风险、益处和程序管理原则的明确干预方式。本综述重点介绍 CIVO 支架植入术的适应症、技术方面和结果。有关 IVS 的其他方面内容将在本系列的其他手稿中阐述:本研究的文献检索仅限于英文文章。采用了三种检索策略,并在 Covidence 软件中对参考文献进行了管理。四名研究人员独立筛选并评估了文章,排除了荟萃分析、临床试验方案和非相关研究。对符合条件的研究进行了全面审查,重点关注临床结果和支架通畅率:文献检索共获得 1,704 项研究,经过筛选和评估,147 项符合资格标准。排除的原因包括重复、内容无关和非髂静脉支架置入:CIVO的成功IVS取决于对患者的精心选择、手术过程中IVUS的持续使用以及对IVS技术细节的关注。
{"title":"Indications, technical aspects, and outcomes of stent placement in chronic iliofemoral venous obstruction","authors":"","doi":"10.1016/j.jvsv.2024.101904","DOIUrl":"10.1016/j.jvsv.2024.101904","url":null,"abstract":"<div><h3>Background</h3><p>Iliofemoral venous stent placement (IVS) has evolved to a well-established endovascular treatment modality for chronic iliofemoral venous obstruction (CIVO). Dedicated venous stents gained approval from the US Food and Drug Administration in 2019 and solidified IVS as a defined intervention with clear indications, contraindications, risks, benefits, and procedural management principles. This review focuses on the indications, technical aspects and outcomes of stenting for CIVO. Other aspects pertaining to IVS are covered in other articles that are a part of this series.</p></div><div><h3>Methods</h3><p>This study conducted a literature search limited to English articles. Three search strategies were used, and references were managed in Covidence software. Four investigators screened and evaluated articles independently, excluding meta-analyses, clinical trial protocols, and nonrelevant studies. Eligible studies, focused on clinical outcomes and stent patencies, underwent thorough review.</p></div><div><h3>Results</h3><p>The literature search yielded 1704 studies, with 147 meeting eligibility criteria after screening and evaluation. Exclusions were based on duplicates, irrelevant content, and noniliac vein stent placement.</p></div><div><h3>Conclusions</h3><p>Successful IVS for CIVO relies on meticulous patient selection, consistent use of intravascular ultrasound examination during procedures and attention to the technical details of IVS.</p></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 5","pages":"Article 101904"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X24002221/pdfft?md5=d53ea0c0f57b905f7c2202230c2702bc&pid=1-s2.0-S2213333X24002221-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis 非复方 Polidocanol 1% 静脉内微泡沫(Varithena)消融与静脉内热消融的疗效比较:系统综述与网络 Meta 分析》。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-04-26 DOI: 10.1016/j.jvsv.2024.101896
<div><h3>Objective</h3><div>We compared the effectiveness and safety of polidocanol 1% endovenous microfoam ablation vs endovenous thermal ablation with radiofrequency or laser energy for treatment of venous insufficiency caused by lower extremity truncal vein incompetence via network meta-analysis of published comparative evidence.</div></div><div><h3>Methods</h3><div>We conducted a systematic literature review following best practices, including a prospective protocol. We screened studies published in English from 2000 to 2023 for randomized and nonrandomized studies reporting direct or indirect comparisons between polidocanol 1% endovenous microfoam and endovenous thermal ablation. Thirteen studies met our eligibility criteria for the network meta-analysis. The co-primary effectiveness outcomes were the closure rate ≥3 months after procedure and the average change in the Venous Clinical Severity Score. For the subgroup of venous ulcer patients, the ulcer healing rate was the primary effectiveness outcome. The secondary outcomes included safety and patient-reported outcomes. Network meta-analyses were conducted on outcomes having sufficient data. Categorical outcomes were summarized using odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity tests and estimates of network inconsistency were used to investigate the robustness of our meta-analysis.</div></div><div><h3>Results</h3><div>We found that polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure (OR, 0.65; 95% CI, 0.36-1.18; <em>P</em> = .16). Although not the primary aim of the study, the network meta-analysis also provided evidence to confirm our supposition that polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds for vein closure (OR, 2.91; 95% CI, 1.58-5.37; <em>P</em> < .01). A sensitivity analysis using the longest available time point for closure in each study, with a minimum of 12 months of follow-up (median, 48 months; range, 12-72 months), showed results similar to those of the main analysis. No association was found between the risk of deep vein thrombosis and the treatment received. The available data were insufficient for a network meta-analysis of Venous Clinical Severity Score improvement and ulcer healing rates.</div></div><div><h3>Conclusions</h3><div>Polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure and deep vein thrombosis risk for chronic venous insufficiency treatment, based on a network meta-analysis of published evidence. Polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds of vein closure. A sensitivity analysis found venous closure findings were robust at follow-up intervals of 12 months or greater and for up to 6 years. New evidence
目的通过对已发表的比较证据进行网络荟萃分析,比较 1%波利多卡醇静脉腔内微泡沫消融术与使用射频或激光能量的静脉腔内热消融术治疗下肢截静脉瓣膜功能不全引起的静脉功能不全的有效性和安全性:我们按照包括前瞻性方案在内的最佳实践进行了系统性文献综述。我们筛选了 2000 年至 2023 年期间用英语发表的随机或非随机研究,这些研究报告了 1%polidocanol 静脉内微泡沫与静脉内热消融之间的直接或间接比较。有 13 项研究符合我们进行网络荟萃分析的资格标准。共同主要有效性结果为术后至少 3 个月的闭合率和静脉临床严重程度评分的平均变化。对于静脉溃疡患者分组,溃疡愈合率是主要疗效结果。次要结果包括安全性和患者报告结果。对有足够数据的结果进行了网络荟萃分析。分类结果采用几率和 95% 置信区间进行总结。为了研究荟萃分析的稳健性,我们采用了敏感性测试和网络不一致性估计:我们发现,在静脉闭合方面,1% 波利多卡诺静脉腔内微泡沫疗法与静脉腔内热消融疗法没有统计学差异(OR 0.65,95% CI 0.36 至 1.18,P=0.16)。虽然这不是研究的主要目的,但网络荟萃分析也提供了证据,证实了我们的推测,即1% Polidocanol 静脉内微泡沫与医生配制的泡沫在统计学上存在差异,静脉闭合的几率更高(OR 2.91,95% CI 1.58 至 5.37,PC 结论:1% Polidocanol 静脉内微泡沫与医生配制的泡沫在统计学上存在差异,静脉闭合的几率更高):根据已发表证据的网络荟萃分析,在慢性静脉功能不全治疗的静脉闭合和深静脉血栓风险方面,1% Polidocanol 静脉内微泡沫与静脉内热消融没有统计学差异。1% Polidocanol 静脉内微泡沫与医生配制的泡沫在统计学上有显著差异,静脉闭合的几率更高。一项敏感性分析发现,静脉闭合结果在随访间隔为12个月或更长时间以及长达6年的情况下都是可靠的。符合本综述纳入标准的新证据将定期纳入动态网络荟萃分析。
{"title":"Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis","authors":"","doi":"10.1016/j.jvsv.2024.101896","DOIUrl":"10.1016/j.jvsv.2024.101896","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;We compared the effectiveness and safety of polidocanol 1% endovenous microfoam ablation vs endovenous thermal ablation with radiofrequency or laser energy for treatment of venous insufficiency caused by lower extremity truncal vein incompetence via network meta-analysis of published comparative evidence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted a systematic literature review following best practices, including a prospective protocol. We screened studies published in English from 2000 to 2023 for randomized and nonrandomized studies reporting direct or indirect comparisons between polidocanol 1% endovenous microfoam and endovenous thermal ablation. Thirteen studies met our eligibility criteria for the network meta-analysis. The co-primary effectiveness outcomes were the closure rate ≥3 months after procedure and the average change in the Venous Clinical Severity Score. For the subgroup of venous ulcer patients, the ulcer healing rate was the primary effectiveness outcome. The secondary outcomes included safety and patient-reported outcomes. Network meta-analyses were conducted on outcomes having sufficient data. Categorical outcomes were summarized using odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity tests and estimates of network inconsistency were used to investigate the robustness of our meta-analysis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;We found that polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure (OR, 0.65; 95% CI, 0.36-1.18; &lt;em&gt;P&lt;/em&gt; = .16). Although not the primary aim of the study, the network meta-analysis also provided evidence to confirm our supposition that polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds for vein closure (OR, 2.91; 95% CI, 1.58-5.37; &lt;em&gt;P&lt;/em&gt; &lt; .01). A sensitivity analysis using the longest available time point for closure in each study, with a minimum of 12 months of follow-up (median, 48 months; range, 12-72 months), showed results similar to those of the main analysis. No association was found between the risk of deep vein thrombosis and the treatment received. The available data were insufficient for a network meta-analysis of Venous Clinical Severity Score improvement and ulcer healing rates.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure and deep vein thrombosis risk for chronic venous insufficiency treatment, based on a network meta-analysis of published evidence. Polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds of vein closure. A sensitivity analysis found venous closure findings were robust at follow-up intervals of 12 months or greater and for up to 6 years. New evidence","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 6","pages":"Article 101896"},"PeriodicalIF":2.8,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of the ankle pump method in a sitting position to evaluate calf perforating veins by color Doppler ultrasound 应用坐姿踝泵法,通过彩色多普勒超声波检查评估小腿穿孔静脉。
IF 3.2 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-04-26 DOI: 10.1016/j.jvsv.2024.101897
Peipei Liu MBBS , Jianxing Huang MBBS , Xueju Zhang PhD, MD , Ruolin Yang MBBS , Shiyuan Yang PhD, MD , Lingli Chen MBBS , Yongyan Gao PhD, MD

Objective

We investigated the feasibility and efficacy of assessing calf perforating veins (PVs) using the ankle pump in a sitting position (AP-sit) method by color Doppler ultrasound.

Methods

We performed a multicenter prospective clinical trial between November 2022 and October 2023. Eligible patients with chronic venous disease and healthy controls were enrolled. The calf PVs were assessed using three different methods: manual compression in a standing position, manual compression in a sitting position, and AP-sit method. The reflux durations and detection rate of incompetent PVs (IPVs) were compared among the three methods. The number and diameter of calf PVs and distribution of IPVs were analyzed.

Results

A total of 50 patients with chronic venous disease and 50 healthy controls were included. There were 173 calves analyzed, including 97 healthy calves and 76 calves with chronic venous disease. The number of PVs per calf was higher in the diseased calves (median, 7.0; interquartile range [IQR], 6.0-8.0) than in the healthy calves (median, 5.0; IQR, 3.0-6.0; P < .001). The diameter of IPVs (median, 2.3 mm; IQR, 2.0-3.1 mm) was larger than that of competent PVs (median, 1.4 mm; IQR, 1.2-1.7 mm). Most of the IPVs (78.8%) were located in the medial and posterior middle of the calf. The reflux duration induced by the AP-sit method was greater than that induced by the manual compression methods (P < .001). Although the AP-sit method had a higher detection rate (92.0%) of IPVs than the manual compression methods (71.7% and 74.3% for standing and sitting, respectively; P < .001), especially in the distal lower leg, the manual compression methods found IPVs not found using the AP-sit method.

Conclusions

Diseased calves with chronic venous disease have more PVs than do healthy calves. IPVs are commonly larger than competent PVs, with most IPVs located in the medial and posterior middle of the calf. Most importantly, the AP-sit method provides a convenient and effective approach for assessing the calf PVs, especially those located in the distal calf, as an alternative or complementary method to traditional manual compression, which is valuable in the daily practice of sonographers.

目的通过彩色多普勒超声波检查,研究在坐姿下使用踝泵法评估小腿穿孔静脉的可行性和有效性:我们在2022年11月至2023年10月期间进行了一项多中心前瞻性临床试验。符合条件的慢性静脉疾病患者和健康对照组均被纳入其中。通过三种不同的方法对小腿穿孔静脉进行评估,即站立位手动压迫、坐位手动压迫和坐位踝泵。比较了三种方法的回流持续时间和无功能穿孔静脉的检出率。分析了小腿穿孔静脉的数量和直径以及无功能穿孔静脉的分布情况:结果:共纳入 50 名慢性静脉疾病患者和 50 名健康对照组。共分析了 173 头小牛,包括 97 头健康小牛和 76 头患有慢性静脉疾病的小牛。患病犊牛每头穿孔静脉的中位数(7.0,四分位间范围 6.0-8.0)高于健康犊牛(5.0,3.0-6.0)(P < 0.001)。无功能穿孔静脉的直径(2.3,2.0-3.1 毫米)大于有功能穿孔静脉的直径(1.4,1.2-1.7 毫米)。大部分无功能穿孔静脉(78.8%)位于小腿内侧和后中部。踝泵法引起的回流持续时间比手动加压法引起的回流持续时间长(P < 0.001)。虽然踝泵法对无功能穿孔静脉的检出率(92.0%)高于人工按压法(站立位和坐位的检出率分别为 71.7% 和 74.3%)(p < 0.001),尤其是在小腿远端,但人工按压法发现了踝泵法未显示的无功能穿孔静脉:结论:患有慢性静脉疾病的小腿比健康小腿有更多的穿孔静脉。结论:患有慢性静脉疾病的患病小腿比健康小腿有更多的穿孔静脉,不称职的小腿穿孔静脉通常比称职的穿孔静脉大,大多数不称职的小腿穿孔静脉位于小腿内侧和后中部。最重要的是,AP-坐姿法为评估小腿穿孔静脉,尤其是位于小腿远端的穿孔静脉提供了一种方便有效的方法,可替代或补充传统的人工按压法,这对超声技师的日常工作非常有价值。
{"title":"Application of the ankle pump method in a sitting position to evaluate calf perforating veins by color Doppler ultrasound","authors":"Peipei Liu MBBS ,&nbsp;Jianxing Huang MBBS ,&nbsp;Xueju Zhang PhD, MD ,&nbsp;Ruolin Yang MBBS ,&nbsp;Shiyuan Yang PhD, MD ,&nbsp;Lingli Chen MBBS ,&nbsp;Yongyan Gao PhD, MD","doi":"10.1016/j.jvsv.2024.101897","DOIUrl":"10.1016/j.jvsv.2024.101897","url":null,"abstract":"<div><h3>Objective</h3><p>We investigated the feasibility and efficacy of assessing calf perforating veins (PVs) using the ankle pump in a sitting position (AP-sit) method by color Doppler ultrasound.</p></div><div><h3>Methods</h3><p>We performed a multicenter prospective clinical trial between November 2022 and October 2023. Eligible patients with chronic venous disease and healthy controls were enrolled. The calf PVs were assessed using three different methods: manual compression in a standing position, manual compression in a sitting position, and AP-sit method. The reflux durations and detection rate of incompetent PVs (IPVs) were compared among the three methods. The number and diameter of calf PVs and distribution of IPVs were analyzed.</p></div><div><h3>Results</h3><p>A total of 50 patients with chronic venous disease and 50 healthy controls were included. There were 173 calves analyzed, including 97 healthy calves and 76 calves with chronic venous disease. The number of PVs per calf was higher in the diseased calves (median, 7.0; interquartile range [IQR], 6.0-8.0) than in the healthy calves (median, 5.0; IQR, 3.0-6.0; <em>P</em> &lt; .001). The diameter of IPVs (median, 2.3 mm; IQR, 2.0-3.1 mm) was larger than that of competent PVs (median, 1.4 mm; IQR, 1.2-1.7 mm). Most of the IPVs (78.8%) were located in the medial and posterior middle of the calf. The reflux duration induced by the AP-sit method was greater than that induced by the manual compression methods (<em>P</em> &lt; .001). Although the AP-sit method had a higher detection rate (92.0%) of IPVs than the manual compression methods (71.7% and 74.3% for standing and sitting, respectively; <em>P</em> &lt; .001), especially in the distal lower leg, the manual compression methods found IPVs not found using the AP-sit method.</p></div><div><h3>Conclusions</h3><p>Diseased calves with chronic venous disease have more PVs than do healthy calves. IPVs are commonly larger than competent PVs, with most IPVs located in the medial and posterior middle of the calf. Most importantly, the AP-sit method provides a convenient and effective approach for assessing the calf PVs, especially those located in the distal calf, as an alternative or complementary method to traditional manual compression, which is valuable in the daily practice of sonographers.</p></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 4","pages":"Article 101897"},"PeriodicalIF":3.2,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X24002154/pdfft?md5=976f40576cccc511a72a2312b0c11b09&pid=1-s2.0-S2213333X24002154-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experimental multiparametric magnetic resonance imaging characterization of iliocaval venous thrombosis pathological changes 髂静脉血栓病理变化的实验性多参数磁共振成像特征描述
IF 3.2 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-04-26 DOI: 10.1016/j.jvsv.2024.101895
Louis Magnus MD, MSc , Adeline Schwein MD, PhD , Ponraj Chinnadurai MBBS-MSST , Killian Fontaine MD , Kyle Autry RT(R) , Dipan J. Shah MD , Kathryn Jane Grande-Allen PhD , Nabil Chakfé MD, PhD , Jean Bismuth MD
<div><h3>Objective</h3><p>Iliocaval thrombotic obstruction is a challenging condition, especially because thrombus age and corresponding pathological remodeling at presentation are unknown, which directly impacts management. Our aim was to assess the ability of magnetic resonance imaging (MRI) in determining age thresholds of experimentally created inferior vena cava (IVC) thrombosis in pigs.</p></div><div><h3>Methods</h3><p>We used a previously described swine model of IVC thrombosis. The animals underwent MRI at baseline, immediately after thrombosis creation, and after a follow-up period extending from 2 to 28 days. Thirteen pigs were divided into three groups according to disease chronicity: acute group (AG; n = 5), subacute group (SAG; n = 4), and chronic group (CG; n = 4), with a mean thrombosis age of 6.4 ± 2.5 days, 15.7 ± 2.8 days, and 28 ± 5.7 days, respectively. A T<sub>1</sub>-weighted volumetric interpolated breath-hold examination sequence was used to anatomically delineate IVC thrombus as a region of interest. Three other MRI sequences were used to assess the thrombus signal.</p></div><div><h3>Results</h3><p>The Kruskal-Wallis test showed a statistically significant difference in T<sub>1</sub> relaxation times after contrast injection (<em>P</em> = .026) between the three groups of chronicity. The AG (360.2 ± 102.5 ms) was significantly different from the CG (336.7 ± 55.2 ms; <em>P</em> = .003), and the SAG (354.1 ± 89.7 ms) was significantly different from the AG (<em>P</em> = .027). There was a statistically significant difference in native T<sub>2</sub> relaxation times (<em>P</em> = .038) between the three groups. The AG (160 ± 86.7 ms) was significantly different from the SAG (142.3 ± 55.4 ms; <em>P</em> = .027), and the SAG was significantly different from the CG (178.4 ± 11.7 ms; <em>P</em> = .004).</p></div><div><h3>Conclusions</h3><p>This study highlighted MRI characteristics in a swine model that might have the potential to significantly differentiate subacute and chronic stages from an acute stage of deep vein thrombosis in humans. Further clinical studies in humans are warranted.</p></div><div><h3>Clinical Relevance</h3><p>In addition to providing a better understanding of venous thrombosis remodeling over time, magnetic resonance imaging has the potential to be a tool that could allow us to characterize the composition of venous thrombus over an interval, allowing for a refined analysis of the local evolution of venous thrombosis. We propose a noninvasive and innovative method to characterize different thresholds of chronicity with magnetic resonance imaging features of central deep vein thrombosis of the inferior vena cava experimentally obtained using a totally endovascular in vivo swine model, mimicking human pathophysiology. Being able to determine these features noninvasively is critical for vascular specialists when it comes to choosing between fibrinolytic therapy, percutaneous thrombectomy, or surgical manageme
目的:静脉血栓性阻塞是一种具有挑战性的疾病,尤其是因为血栓年龄和发病时相应的病理重塑情况不明,这直接影响了治疗。我们的目的是评估磁共振成像(MRI)在确定猪实验性下腔静脉(IVC)血栓年龄阈值方面的能力:我们使用了之前描述过的猪下腔静脉血栓形成模型。动物在基线、血栓形成后立即和随访 2-28 天后接受磁共振成像。13 只动物根据疾病的慢性程度分为 3 组:急性组(AG,N1 = 5)、亚急性组(SAG,N2 = 4)和慢性组(CG,N3 = 4),平均血栓形成年龄分别为 6.4 ± 2.5 天、15.7 ± 2.8 天和 28 ± 5.7 天。采用 T1 加权容积插值屏气检查序列,将 IVC 血栓作为感兴趣区进行解剖学划分。其他三种磁共振成像序列用于评估血栓信号:Kruskal-Wallis显示,3组慢性病患者注射造影剂后的T1弛豫时间差异有统计学意义(P = .026):AG(360.2 ± 102.5)与 CG(336.7 ± 55.2 ms;P = .003)有显著差异,SAG(354.1 ± 89.7 ms)与 AG(P = .027)有显著差异。三组之间的原生 T2 松弛时间差异有统计学意义(P = .038):AG(160 ± 86.7 ms)与 SAG(142.3 ± 55.4 ms;P = .027)显著不同,SAG 与 CG(178.4 ± 11.7 ms;P = .004)显著不同:本研究强调了猪模型的核磁共振成像特征,这些特征有可能显著区分人类深静脉血栓的亚急性和慢性阶段与急性阶段。有必要在人类中开展进一步的临床研究。
{"title":"Experimental multiparametric magnetic resonance imaging characterization of iliocaval venous thrombosis pathological changes","authors":"Louis Magnus MD, MSc ,&nbsp;Adeline Schwein MD, PhD ,&nbsp;Ponraj Chinnadurai MBBS-MSST ,&nbsp;Killian Fontaine MD ,&nbsp;Kyle Autry RT(R) ,&nbsp;Dipan J. Shah MD ,&nbsp;Kathryn Jane Grande-Allen PhD ,&nbsp;Nabil Chakfé MD, PhD ,&nbsp;Jean Bismuth MD","doi":"10.1016/j.jvsv.2024.101895","DOIUrl":"10.1016/j.jvsv.2024.101895","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;Iliocaval thrombotic obstruction is a challenging condition, especially because thrombus age and corresponding pathological remodeling at presentation are unknown, which directly impacts management. Our aim was to assess the ability of magnetic resonance imaging (MRI) in determining age thresholds of experimentally created inferior vena cava (IVC) thrombosis in pigs.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We used a previously described swine model of IVC thrombosis. The animals underwent MRI at baseline, immediately after thrombosis creation, and after a follow-up period extending from 2 to 28 days. Thirteen pigs were divided into three groups according to disease chronicity: acute group (AG; n = 5), subacute group (SAG; n = 4), and chronic group (CG; n = 4), with a mean thrombosis age of 6.4 ± 2.5 days, 15.7 ± 2.8 days, and 28 ± 5.7 days, respectively. A T&lt;sub&gt;1&lt;/sub&gt;-weighted volumetric interpolated breath-hold examination sequence was used to anatomically delineate IVC thrombus as a region of interest. Three other MRI sequences were used to assess the thrombus signal.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The Kruskal-Wallis test showed a statistically significant difference in T&lt;sub&gt;1&lt;/sub&gt; relaxation times after contrast injection (&lt;em&gt;P&lt;/em&gt; = .026) between the three groups of chronicity. The AG (360.2 ± 102.5 ms) was significantly different from the CG (336.7 ± 55.2 ms; &lt;em&gt;P&lt;/em&gt; = .003), and the SAG (354.1 ± 89.7 ms) was significantly different from the AG (&lt;em&gt;P&lt;/em&gt; = .027). There was a statistically significant difference in native T&lt;sub&gt;2&lt;/sub&gt; relaxation times (&lt;em&gt;P&lt;/em&gt; = .038) between the three groups. The AG (160 ± 86.7 ms) was significantly different from the SAG (142.3 ± 55.4 ms; &lt;em&gt;P&lt;/em&gt; = .027), and the SAG was significantly different from the CG (178.4 ± 11.7 ms; &lt;em&gt;P&lt;/em&gt; = .004).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;This study highlighted MRI characteristics in a swine model that might have the potential to significantly differentiate subacute and chronic stages from an acute stage of deep vein thrombosis in humans. Further clinical studies in humans are warranted.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical Relevance&lt;/h3&gt;&lt;p&gt;In addition to providing a better understanding of venous thrombosis remodeling over time, magnetic resonance imaging has the potential to be a tool that could allow us to characterize the composition of venous thrombus over an interval, allowing for a refined analysis of the local evolution of venous thrombosis. We propose a noninvasive and innovative method to characterize different thresholds of chronicity with magnetic resonance imaging features of central deep vein thrombosis of the inferior vena cava experimentally obtained using a totally endovascular in vivo swine model, mimicking human pathophysiology. Being able to determine these features noninvasively is critical for vascular specialists when it comes to choosing between fibrinolytic therapy, percutaneous thrombectomy, or surgical manageme","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 4","pages":"Article 101895"},"PeriodicalIF":3.2,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X24002130/pdfft?md5=c72c453182f954e9e0887d50b763ebc1&pid=1-s2.0-S2213333X24002130-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A scoping review of scores or grading systems for pelvic venous disorders 盆腔静脉疾病(PeVD)评分或分级系统范围综述
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-04-25 DOI: 10.1016/j.jvsv.2024.101901

Background

Pelvic venous disorders (PeVD) encompass a variety of conditions linked to chronic pelvic pain in women. However, PeVD remain underdiagnosed due to the absence of universally accepted diagnostic criteria. The complexity of PeVD classifications across specialties leads to delays in treatment. This scoping review aims to fill a gap in PeVD diagnosis and management by identifying all existing scoring or grading systems to lay the foundation for standardized clinical scoring tools for PeVD.

Methods

This scoping review was undertaken according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping reviews. Online databases were searched up to April 2023. Studies implementing a scoring or grading system for patients with confirmed or suspected PeVD were included. Scores or grading systems were classified into four main categories based on their use in the study: screening, diagnosis, measure of disease severity, and measure of response to treatment.

Results

Of the 2976 unique records identified, 82 were reviewed in full, and 20 were included in this study. The publication dates ranged from 1984 to 2023 (median, 2018; interquartile range, 2003-2022). A total of 21 scores and/or grading systems were identified. Of these 21 scores, 10 (47.6%) were clinical scores, and 10 (47.6%) were scores based on radiological findings; one study included a score that used both clinical and radiological findings. The identified scores were used in various settings. Of the 21 scores, 2 (9.52%) were used for screening in a tertiary care setting; 3 (14.3%) were used to establish the PeVD diagnosis; 8 (38.1%) were used to assess disease severity; and 8 (38.1%) were used as measures of response to treatment. Of the eight scores assessing disease severity, four (50.0%) assessed the degree of dilatation of pelvic veins and four (50%) assessed the severity of reflux. Only three of the scores were validated.

Conclusions

This scoping review identified a range of scoring and grading systems for PeVD. We note a lack of a validated scoring system, both clinical and radiological, for screening and assessment of disease severity. This is an important first step in developing validated disease-specific scoring systems for patient screening, appropriate referral, assessment of symptom severity, and assessment of the response to treatment.
背景盆腔静脉疾病(Pelvic venous disorders,PVD)包括多种与女性慢性盆腔疼痛有关的疾病。然而,由于缺乏公认的诊断标准,PeVD 的诊断率仍然偏低。各专科对 PeVD 分类的复杂性导致了治疗的延误。本范围界定综述旨在通过确定所有现有的评分或分级系统来填补 PeVD 诊断和管理方面的空白,从而为 PeVD 的标准化临床评分工具奠定基础。对截至 2023 年 4 月的在线数据库进行了检索。纳入了对确诊或疑似 PeVD 患者实施评分或分级系统的研究。评分或分级系统根据其在研究中的应用分为四大类:筛查、诊断、疾病严重程度测量和治疗反应测量。发表日期从 1984 年到 2023 年不等(中位数为 2018 年;四分位间范围为 2003-2022 年)。共确定了 21 项评分和/或分级系统。在这21个评分中,10个(47.6%)是临床评分,10个(47.6%)是基于放射学检查结果的评分;有一项研究的评分同时使用了临床和放射学检查结果。已确定的评分在不同的环境中使用。在 21 个评分中,2 个(9.52%)用于三级医疗机构的筛查;3 个(14.3%)用于确定 PeVD 诊断;8 个(38.1%)用于评估疾病严重程度;8 个(38.1%)用于衡量对治疗的反应。在评估疾病严重程度的八项评分中,四项(50.0%)评估盆腔静脉的扩张程度,四项(50%)评估回流的严重程度。结论本次范围界定审查发现了一系列针对 PeVD 的评分和分级系统。我们注意到在临床和放射学方面都缺乏一个有效的评分系统来筛查和评估疾病的严重程度。这是为患者筛查、适当转诊、症状严重程度评估和治疗反应评估开发有效的特定疾病评分系统迈出的重要的第一步。
{"title":"A scoping review of scores or grading systems for pelvic venous disorders","authors":"","doi":"10.1016/j.jvsv.2024.101901","DOIUrl":"10.1016/j.jvsv.2024.101901","url":null,"abstract":"<div><h3>Background</h3><div>Pelvic venous disorders (PeVD) encompass a variety of conditions linked to chronic pelvic pain in women. However, PeVD remain underdiagnosed due to the absence of universally accepted diagnostic criteria. The complexity of PeVD classifications across specialties leads to delays in treatment. This scoping review aims to fill a gap in PeVD diagnosis and management by identifying all existing scoring or grading systems to lay the foundation for standardized clinical scoring tools for PeVD.</div></div><div><h3>Methods</h3><div>This scoping review was undertaken according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping reviews. Online databases were searched up to April 2023. Studies implementing a scoring or grading system for patients with confirmed or suspected PeVD were included. Scores or grading systems were classified into four main categories based on their use in the study: screening, diagnosis, measure of disease severity, and measure of response to treatment.</div></div><div><h3>Results</h3><div>Of the 2976 unique records identified, 82 were reviewed in full, and 20 were included in this study. The publication dates ranged from 1984 to 2023 (median, 2018; interquartile range, 2003-2022). A total of 21 scores and/or grading systems were identified. Of these 21 scores, 10 (47.6%) were clinical scores, and 10 (47.6%) were scores based on radiological findings; one study included a score that used both clinical and radiological findings. The identified scores were used in various settings. Of the 21 scores, 2 (9.52%) were used for screening in a tertiary care setting; 3 (14.3%) were used to establish the PeVD diagnosis; 8 (38.1%) were used to assess disease severity; and 8 (38.1%) were used as measures of response to treatment. Of the eight scores assessing disease severity, four (50.0%) assessed the degree of dilatation of pelvic veins and four (50%) assessed the severity of reflux. Only three of the scores were validated.</div></div><div><h3>Conclusions</h3><div>This scoping review identified a range of scoring and grading systems for PeVD. We note a lack of a validated scoring system, both clinical and radiological, for screening and assessment of disease severity. This is an important first step in developing validated disease-specific scoring systems for patient screening, appropriate referral, assessment of symptom severity, and assessment of the response to treatment.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 6","pages":"Article 101901"},"PeriodicalIF":2.8,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of native iliac vein aspect ratio on initial clinical presentation and outcomes following stenting for symptomatic chronic iliofemoral venous obstruction 原生髂静脉长宽比对症状性慢性髂股静脉阻塞支架置入术后初期临床表现和疗效的影响
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-04-25 DOI: 10.1016/j.jvsv.2024.101900
<div><h3>Objective</h3><p>Venous stenting has become the first line of treatment for patients with symptomatic chronic iliofemoral venous obstruction (CIVO) in whom conservative therapy has failed. Intravascular ultrasound (IVUS) interrogation with the use of normal minimal luminal diameters or areas has become the standard to confirm the diagnosis and determine the adequacy of stenting. However, the aspect ratio (ratio between the maximal and minimal luminal diameters) has also been put forth as a possible metric for determining stent adequacy. This study explores the utility of the native iliac vein and stent aspect ratios in determining the initial presentation and outcomes after stenting.</p></div><div><h3>Methods</h3><p>A retrospective analysis of contemporaneously entered data from patients who underwent stenting for quality of life (QoL)-impairing clinical manifestations of CIVO for whom conservative therapy had failed formed the study cohort. The limbs were grouped into three at the time of intervention using the IVUS-determined native vein aspect ratio: group I, those with a ratio of ≤1.4; group II, those with a ratio of 1.41 to 1.99; and group III, those with a ratio of ≥2. The characteristics appraised initially and after stenting included the venous clinical severity score, grade of swelling (GOS), visual analog scale (VAS) for pain score, and the CIVIQ-20 QoL score. Analysis of variance and paired and unpaired <em>t</em> tests were used for comparison of clinical and QoL variables, and Kaplan-Meier analysis was used to evaluate stent patency, with the log-rank test used to discriminate between different curves.</p></div><div><h3>Results</h3><p>There were a total of 236 limbs (236 patients). The median age for the entire cohort was 62 years (range, 16-92 years). There were 161 women in the study, and left laterality was more common (137 limbs). Post-thrombotic obstruction was noted in 201 limbs (86%). The median body mass index was 36 kg/m<sup>2</sup>. There were 54 (23%), 64 (27%), and 118 (50%) limbs in groups I, II, and III, respectively. The median follow-up was 65 months. For the entire cohort, after stenting, the venous clinical severity score improved from 6 to 4 (<em>P</em> < .0001) at 3 months and remained at 4 at 6 months (<em>P</em> < .0001), 12 months (<em>P</em> < .0001), and 24 months (<em>P</em> < .0001). The GOS for the entire cohort improved from 3 to 1 (<em>P</em> < .0001) at 3 months and remained at 1 at 6 months (<em>P</em> < .0001), 12 months (<em>P</em> < .0001), and 24 months (<em>P</em> < .0001). The VAS for pain score for the entire cohort improved from 7 to 0 (<em>P</em> < .0001) at 3 months, increased to 2 (<em>P</em> < .0001) at 6 months, and remained at 2 (<em>P</em> < .0001) at 12 months. At 24 months, the VAS for pain score worsened to 3 (<em>P</em> < .0001). For the entire cohort, the CIVIQ-20 score improved from 62 to 40 (<em>P</em> < .0001). There was no differen
目的 静脉支架植入术已成为保守治疗无效的无症状慢性髂股静脉阻塞(CIVO)患者的一线治疗方法。使用正常最小管腔直径或面积进行血管内超声(IVUS)检查已成为确诊和确定支架植入是否充分的标准。然而,长径比(最大管腔直径与最小管腔直径之比)也被认为是判断支架是否足够的一个可能指标。本研究探讨了原生髂静脉和支架长径比在确定支架术后的初始表现和预后方面的实用性。研究方法:对因生活质量(QoL)受影响的 CIVO 临床表现而接受支架术且保守治疗无效的患者的同期输入数据进行回顾性分析,形成研究队列。介入治疗时,根据IVUS确定的原生静脉长宽比将肢体分为三组:第一组,长宽比≤1.4;第二组,长宽比在1.41至1.99之间;第三组,长宽比≥2。最初和支架植入后的特征评估包括静脉临床严重程度评分、肿胀等级(GOS)、疼痛视觉模拟量表(VAS)评分和 CIVIQ-20 QoL 评分。方差分析、配对和非配对 t 检验用于比较临床和 QoL 变量,Kaplan-Meier 分析用于评估支架的通畅性,log-rank 检验用于区分不同的曲线。整个组群的中位年龄为 62 岁(16-92 岁)。研究中有 161 名女性,左侧肢体更常见(137 例)。血栓后阻塞的肢体有 201 例(86%)。体重指数中位数为 36 kg/m2。I 组、II 组和 III 组分别有 54 条(23%)、64 条(27%)和 118 条(50%)肢体。中位随访时间为 65 个月。就整个组别而言,支架植入术后,静脉临床严重程度评分在 3 个月时从 6 分降至 4 分(P < .0001),在 6 个月(P < .0001)、12 个月(P < .0001)和 24 个月(P < .0001)时仍为 4 分。整个组群的 GOS 在 3 个月时从 3 分降至 1 分(P < .0001),并在 6 个月(P < .0001)、12 个月(P < .0001)和 24 个月(P < .0001)时保持在 1 分。整个组群的疼痛 VAS 评分在 3 个月时从 7 分降至 0 分(P < .0001),在 6 个月时升至 2 分(P < .0001),在 12 个月时保持在 2 分(P < .0001)。24 个月时,VAS 疼痛评分恶化为 3(P < .0001)。整个组群的 CIVIQ-20 评分从 62 分提高到 40 分(P < .0001)。在基线或干预后 6、12 和 24 个月,两组的 GOS、VAS 疼痛评分或 CIVIQ-20 评分均无差异。60 个月时,I 组的主要支架通畅率为 89%,II 组为 80%,III 组为 75%(P = .85)。I 组的主要辅助支架通畅率为 100%,II 组为 98%,III 组为 98%(P = .5)。II组和III组的二次通畅率为100%(P = .5)。结论原生静脉长宽比似乎并不决定最初的临床表现或 QoL,也不影响 CIVO 支架置入术后的临床或 QoL 结果。支架术后,没有患者的纵横比为2,97%的患者纵横比≤1.4,其余3%的患者纵横比为1.41至1.99。IVUS确定的最小横截面管腔面积而非纵横比应用于确诊CIVO和评估支架植入的充分性。
{"title":"Impact of native iliac vein aspect ratio on initial clinical presentation and outcomes following stenting for symptomatic chronic iliofemoral venous obstruction","authors":"","doi":"10.1016/j.jvsv.2024.101900","DOIUrl":"10.1016/j.jvsv.2024.101900","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;Venous stenting has become the first line of treatment for patients with symptomatic chronic iliofemoral venous obstruction (CIVO) in whom conservative therapy has failed. Intravascular ultrasound (IVUS) interrogation with the use of normal minimal luminal diameters or areas has become the standard to confirm the diagnosis and determine the adequacy of stenting. However, the aspect ratio (ratio between the maximal and minimal luminal diameters) has also been put forth as a possible metric for determining stent adequacy. This study explores the utility of the native iliac vein and stent aspect ratios in determining the initial presentation and outcomes after stenting.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;A retrospective analysis of contemporaneously entered data from patients who underwent stenting for quality of life (QoL)-impairing clinical manifestations of CIVO for whom conservative therapy had failed formed the study cohort. The limbs were grouped into three at the time of intervention using the IVUS-determined native vein aspect ratio: group I, those with a ratio of ≤1.4; group II, those with a ratio of 1.41 to 1.99; and group III, those with a ratio of ≥2. The characteristics appraised initially and after stenting included the venous clinical severity score, grade of swelling (GOS), visual analog scale (VAS) for pain score, and the CIVIQ-20 QoL score. Analysis of variance and paired and unpaired &lt;em&gt;t&lt;/em&gt; tests were used for comparison of clinical and QoL variables, and Kaplan-Meier analysis was used to evaluate stent patency, with the log-rank test used to discriminate between different curves.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;There were a total of 236 limbs (236 patients). The median age for the entire cohort was 62 years (range, 16-92 years). There were 161 women in the study, and left laterality was more common (137 limbs). Post-thrombotic obstruction was noted in 201 limbs (86%). The median body mass index was 36 kg/m&lt;sup&gt;2&lt;/sup&gt;. There were 54 (23%), 64 (27%), and 118 (50%) limbs in groups I, II, and III, respectively. The median follow-up was 65 months. For the entire cohort, after stenting, the venous clinical severity score improved from 6 to 4 (&lt;em&gt;P&lt;/em&gt; &lt; .0001) at 3 months and remained at 4 at 6 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001), 12 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001), and 24 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001). The GOS for the entire cohort improved from 3 to 1 (&lt;em&gt;P&lt;/em&gt; &lt; .0001) at 3 months and remained at 1 at 6 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001), 12 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001), and 24 months (&lt;em&gt;P&lt;/em&gt; &lt; .0001). The VAS for pain score for the entire cohort improved from 7 to 0 (&lt;em&gt;P&lt;/em&gt; &lt; .0001) at 3 months, increased to 2 (&lt;em&gt;P&lt;/em&gt; &lt; .0001) at 6 months, and remained at 2 (&lt;em&gt;P&lt;/em&gt; &lt; .0001) at 12 months. At 24 months, the VAS for pain score worsened to 3 (&lt;em&gt;P&lt;/em&gt; &lt; .0001). For the entire cohort, the CIVIQ-20 score improved from 62 to 40 (&lt;em&gt;P&lt;/em&gt; &lt; .0001). There was no differen","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"12 5","pages":"Article 101900"},"PeriodicalIF":2.8,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213333X2400218X/pdfft?md5=2bedfe9d1118d4cd7b104ed71385be03&pid=1-s2.0-S2213333X2400218X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140791045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of vascular surgery. Venous and lymphatic disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1